Skip to main content

Table 4 Relative risk of second primary cancer by type of first primary cancer and time period

From: The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study

 

1981–1989

1990–1999

2000–2009

First primary cancer

O

E

SIR

95%CI

O

E

SIR

95%CI

O

E

SIR

95%CI

Oral Cavity & Pharynx

385

115

3.36

(2.89–3.82)

681

190

3.58

(3.21–3.95)

707

210

3.37

(3.05–3.70)

Oesophagus

32

11

2.93

(1.79–4.08)

79

31

2.54

(1.93–3.15)

97

50

1.95

(1.52–2.38)

Stomach

117

100

1.18

(0.90–1.45)

165

134

1.24

(0.98–1.49)

132

112

1.18

(0.92–1.44)

Colorectal

761

628

1.22

(1.01–1.43)

1183

1028

1.16

(0.96–1.36)

1339

1137

1.18

(1.00–1.37)

Liver & Intrahepatic Bile Ducts

9

5

1.79

(0.35–3.23)

25

22

1.12

(0.62–1.63)

72

52

1.37

(1.03–1.72)

Pancreas

15

11

1.34

(0.53–2.15)

22

23

0.98

(0.50–1.45)

42

37

1.14

(0.75–1.53)

Larynx

170

73

2.32

(1.92–2.71)

247

94

2.63

(2.27–3.00)

253

89

2.83

(2.44–3.23)

Lung

291

171

1.70

(1.49–1.91)

433

266

1.63

(1.46–1.80)

530

325

1.63

(1.47–1.79)

Skin Melanoma

264

212

1.25

(1.05–1.44)

536

441

1.22

(1.05–1.39)

709

593

1.20

(1.04–1.36)

Breast female

721

756

0.96

(0.81–1.10)

1205

1301

0.93

(0.81–1.05)

1435

1516

0.95

(0.85–1.05)

Cervix Uteri

97

57

1.71

(1.34–2.08)

86

61

1.42

(1.08–1.75)

65

40

1.63

(1.18–2.07)

Corpus Uteri & NOS

197

193

1.02

(0.86–1.19)

285

251

1.14

(0.96–1.31)

309

243

1.27

(1.08–1.47)

Ovary

57

48

1.18

(0.84–1.52)

100

78

1.28

(1.00–1.56)

70

81

0.86

(0.64–1.09)

Prostate

608

858

0.71

(0.59–0.84)

1544

2203

0.70

(0.60–0.81)

2487

3137

0.79

(0.72–0.87)

Testis

31

22

1.43

(0.86–1.99)

54

38

1.43

(1.01–1.85)

55

37

1.49

(1.06–1.92)

Kidney

123

95

1.29

(1.03–1.55)

207

186

1.11

(0.94–1.29)

296

197

1.50

(1.28–1.72)

Bladder

328

242

1.36

(1.14–1.58)

514

352

1.47

(1.22–1.71)

470

277

1.70

(1.43–1.98)

Brain & Central Nerves

15

10

1.43

(0.58–2.28)

24

22

1.11

(0.60–1.62)

39

27

1.43

(0.93–1.93)

Thyroid

58

48

1.22

(0.87–1.57)

102

76

1.35

(1.06–1.64)

136

95

1.44

(1.18–1.70)

Hodgkin Lymphoma

41

17

2.40

(1.58–3.21)

59

26

2.27

(1.63–2.90)

77

29

2.63

(1.99–3.27)

Non Hodgkin Lymphoma

185

138

1.34

(1.10–1.59)

347

265

1.31

(1.13–1.50)

444

318

1.40

(1.21–1.59)

Multiple Myeloma

58

45

1.28

(0.91–1.66)

83

77

1.08

(0.81–1.35)

116

103

1.12

(0.89–1.36)

Leukaemia

167

106

1.58

(1.27–1.89)

246

168

1.47

(1.21–1.73)

327

206

1.59

(1.35–1.84)

All Cancers

5052

4172

1.21

(1.07–1.36)

8752

7679

1.14

(1.00–1.28)

10,837

9308

1.17

(1.05–1.28)

  1. O: number of observed cases
  2. E: number of expected cases
  3. SIR: standardized incidence ratio
  4. 95%CI: 95% confidence intervals